This paper provides an overview of multiple sclerosis (MS), a chronic autoimmune condition characterized by the destruction of the myelin sheath within the central nervous system. It examines how MS affects the nervous system through neurodegeneration, grey and white matter lesions, and complex immunological processes involving CD4+ T cells and cytokines. The paper also reviews current treatment approaches — including beta interferons, immunosuppressants, corticosteroids, and muscle relaxants — alongside supportive therapies such as physical and occupational therapy and counseling. Finally, it addresses the current state of MS prevention, noting that no definitive preventive measures exist until the disease's root cause is better understood.
Multiple sclerosis (MS) is a chronic autoimmune condition that affects physical movement, function, and sensation. The disease develops following the destruction of the myelin sheath — the insulating layer surrounding neurons — within an individual's central nervous system (CNS) (Cengage Learning, 2013). Symptoms typically begin appearing in early adulthood, significantly impacting patients' domestic, social, and professional lives. Because the absence of myelin slows the conduction of action potentials, the disorder manifests as functional impairment with potentially destructive effects on patient behavior. MS often involves a relatively progressive onset of behavioral deficiencies and neurological symptoms (Hoang & Shepherd, 2010).
Chronic, advancing cognitive deterioration in MS has been attributed to a neuropathological, neurodegenerative disease process — specifically, diffuse brain atrophy and axonal destruction. Additionally, white matter lesions and brain atrophy are known to play a significant role in cognitive dysfunction among individuals diagnosed with MS. However, more recent research suggests that grey matter lesions may also exert a substantial influence on cognitive function (Rocca, Pravata & Valsasina, 2015).
Grey and white matter tissue inflammation within the central nervous system, caused by cytokine activity and the infiltration of focal immune cells, is the primary driver of MS-related damage. A large body of research indicates that CD4+ T cells — also known as T helper (Th) cells — play a central role, and that the adaptive immune responses triggered through T lymphocyte–APC (antigen-presenting cell) interaction contribute substantially to the onset and progression of MS.
Pathogen-associated molecules bind simultaneously with toll-like receptors on APCs. The subsequent release of interleukins such as IL-4, IL-12, and IL-23, along with other cytokines, triggers the differentiation of CD4+ T cells into Th1, Th17, or Th2 phenotypes, each of which releases distinct cytokines. Type II interferon — also known as interferon gamma (IFN-γ) — and tumor necrosis factor alpha (TNF-α) are pro-inflammatory cytokines critical to both adaptive and innate immunity. Th1 cells release these cytokines, which can promote inflammation by suppressing Th2 differentiation.
Th2 cells produce IL-13 and IL-4 — anti-inflammatory cytokines that each affect immune cells differently. IL-13 secretes matrix metalloproteinase, particularly during allergic inflammation, while IL-4 reduces pathological inflammation by increasing M2/repair macrophages and alternatively activating pro-inflammatory M1 macrophages. Th17 cells — another subtype of CD4+ T cells — induce various cytokines that further promote inflammation (Ghasemi, Razavi & Nikzad, 2017). Understanding these immunological pathways is central to ongoing efforts to develop targeted MS therapies.
As of 2016, multiple sclerosis has no known cure or disease-prevention approach. Treatment varies based on the severity and range of symptoms. Some patients manage well without therapy, or with minimal therapy, for extended periods. Heat is known to aggravate symptoms, whereas cool baths or swimming may provide relief. Numerous drug classes have been developed to facilitate MS treatment, with additional options being created and tested in recent decades. Certain medications work better for specific forms of MS, though many carry the risk of serious side effects, and not every medication is suitable for every patient. Among the medications commonly used in MS treatment are the following:
Beta interferons. These man-made protein molecules function similarly to the natural proteins released by immune system cells when fighting infections. They are administered by injection multiple times per week.
Immunosuppressants and immune system blockers. When injected, these drugs work to inhibit the immune system's attack on the myelin sheath.
Corticosteroids. Primarily administered to patients with progressive MS, these drugs can cause adverse effects if used over a prolonged period.
"Pharmacological and supportive therapies for MS"
"Lifestyle measures and limits of MS prevention"
Always verify citation format against your institution’s current style guide requirements.